Soligenix Inc (SNGX)

[io_io]

<<<<<"the FDA requested that DOR review its existing clinical data from both its randomized, double-blind, placebo-controlled trials and highlight pertinent additional data that could provide a more comprehensive picture of orBec®'s clinical effect">>>>


Thinking again, you could look at this a few ways.

Would it have been possible for the FDA to approve orBec last July, following the ODAC no-vote and also the DNDN decision ? If not, then you kick down-field for time.

Also, the fact that the FDA said, as early as June 13th : "give us some data, any data" sounds as if they wanted to stall, and were not stuck on any one issue.